• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
1AD

ADALTA LIMITED - News & Media

0.00% ! 0.3¢
Market Cap $8.927M  !
Healthcare Biotechnology
Add to My Watchlist

AdAlta Limited is an Australia-based drug discovery and development company. The Company... AdAlta Limited is an Australia-based drug discovery and development company. The Company is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company's principal activity is to develop its ibody platform with a focus on its lead candidate AD-114, a treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Its i-body AD-114 drug candidate is used for treatment in various fibrosis related eye diseases to support the pre-clinical development of the eye fibrosis indication. The Company's AD-114 has shown both anti-fibrotic and anti-inflammatory effects in various animal models. The Company's AD-114 is used in various therapeutic applications for fibrosis diseases of the liver, skin, kidney and heart. AD-114 has completed pre-clinical studies in vitro (in the lab) and in vivo (in animals) data obtained.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

'East to West': AdAlta unveils new strategy to find drug candidates, but appears to've ditched AD-214

AdAlta plans to take cell therapy candidates from Southeast Asia, firm them in Aus tests, and then licence products to Europe and America.

06 Feb 2025 11:31 (AEDT)

Health microcap AdAlta claims world-first malaria "breakthrough"

AdAlta (ASX:1AD) has seen its shares lift almost five per cent today on reporting a world-first malaria "breakthrough".

19 Dec 2023 14:36 (AEDT)

AdAlta (ASX:1AD) welcomes Yuuwa as new substantial shareholders

AdAlta (ASX:1AD) has welcomed two new investors associated via the Yuuwa Capital Venture Capital fund as substantial shareholders.

24 Jan 2023 14:13 (AEDT)

AdAlta (ASX:1AD) receives second Japanese patent for AD-214

AdAlta (ASX:1AD) has been granted its second patent by the Japanese Patent Office for its lead program, AD-214.

10 Jan 2023 10:54 (AEDT)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
Start T rading
Last
0.3¢ 		Change
0.000(0.00%) 		Mkt cap ! $8.927M
Open High Low Volume
0.3¢ 0.3¢ 0.3¢ 263K

Buyers (Bids)

Vol. Price($)
22402218 0.3¢
 

Sellers (Offers)

Price($) Vol.
0.4¢ 14374438
Last trade - 07.00am 31/07/2026 (20 minute delay) ?
1AD (ASX) Chart

Top Stories

AFT Pharmaceutical's multi-billion R&D opportunity

Welcome to HotCopper’s latest Watchlist, where we’ve been joined by AFT Pharmaceuticals (ASX:AFP) founder and chief executive Hartley Atkinson to discuss its expanding global reach and the @tentative” FDA approval the company has just hauled i...
Expert Exchange: SpaceX plummets back down to earth after explosive IPO debut SpaceX has revisited its $135 listing price after an explosive IPO as investors reassess lofty valuations ahead of its first earnings report.
Lodestar Minerals advances Ned's Creek gold on back of high-grade Central Park results Lodestar Minerals has received further encouraging assay results from the Central Park prospect within the Ned’s Creek gold project in WA.
LISTEN: HotCopper's Penny Drop Podcast #1 – Uranium deals, PFS misses, & an Ebola opportunity HotCopper editor Isaac McIntyre takes you through all the biggest sub-$1 movers on the ASX markets and across the HotCopper forums ⁠you should be watching in the new week, using the forum’s HotList tracking page.Hear from all the ASX-listed companies that were at the RIU R...
Diablo expands critical minerals footprint at Star Range Welcome to HotCopper’s latest Watchlist, where this week we’ve been joined by Diablo Resources (ASX:DBO) CEO Lyle Thorne to discuss recent exploration that’s @expanded the scale” at Star Range in Beaver County, Utah.Listen to t...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.